{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:24:41Z","timestamp":1793813081758,"version":"4.6.1"},"reference-count":125,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seminarsinnephrology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.semnephrol.2025.151570","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T08:29:24Z","timestamp":1741854564000},"page":"151570","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Post-transplant IgA Nephropathy"],"prefix":"10.1016","volume":"44","author":[{"given":"Song C.","family":"Ong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce A.","family":"Julian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.semnephrol.2025.151570_bib0001","first-page":"939","article-title":"IgA glomerular deposits in renal disease","volume":"1","author":"Berger","year":"1969","journal-title":"Transplant Proc."},{"issue":"9","key":"10.1016\/j.semnephrol.2025.151570_bib0002","first-page":"694","article-title":"Les depots intercapillaires d'IgA-IgG [intercapillary deposits of IgA-IgG]","volume":"74","author":"Berger","year":"1968","journal-title":"J Urol Nephrol (Paris)"},{"issue":"23","key":"10.1016\/j.semnephrol.2025.151570_bib0003","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12237361","article-title":"Colocalization of IgG and IgA heavy chains with kappa and lambda light chains in glomerular deposits of IgA nephropathy patients using high-resolution confocal microscopy and correlation with Oxford MEST-C scores","volume":"12","author":"Rizk","year":"2023","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.semnephrol.2025.151570_bib0004","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/ndt\/gfq665","article-title":"The incidence of primary glomerulonephritis worldwide: A systematic review of the literature","volume":"26","author":"McGrogan","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1016\/j.semnephrol.2025.151570_bib0005","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","article-title":"Long-term outcomes in IgA nephropathy","volume":"18","author":"Pitcher","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.semnephrol.2025.151570_bib0006","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ekir.2017.08.008","article-title":"Life expectancy for patients from the southeastern united states with IgA nephropathy","volume":"3","author":"Hastings","year":"2018","journal-title":"Kidney Int Rep"},{"issue":"9","key":"10.1016\/j.semnephrol.2025.151570_bib0007","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1097\/TP.0000000000001093","article-title":"Recurrent IgA nephropathy after kidney transplantation","volume":"100","author":"Wyld","year":"2016","journal-title":"Transplantation."},{"issue":"2","key":"10.1016\/j.semnephrol.2025.151570_bib0008","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1056\/NEJMoa013036","article-title":"Risk of renal allograft loss from recurrent glomerulonephritis","volume":"347","author":"Briganti","year":"2002","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.semnephrol.2025.151570_bib0009","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.ekir.2018.07.021","article-title":"Clinical characteristics and treatment patterns of children and adults with IgA nephropathy or IgA vasculitis: findings from the CureGN study","volume":"3","author":"Selewski","year":"2018","journal-title":"Kidney Int Rep."},{"issue":"4","key":"10.1016\/j.semnephrol.2025.151570_bib0010","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/ndt\/gfx189","article-title":"Glomerular disease frequencies by race, sex and region: results from the international kidney biopsy survey","volume":"33","author":"O'Shaughnessy","year":"2018","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1016\/j.semnephrol.2025.151570_bib0011","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1681\/ASN.2016060670","article-title":"Prognostic value of serum biomarkers of autoimmunity for recurrence of IgA nephropathy after kidney transplantation","volume":"28","author":"Berthoux","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.semnephrol.2025.151570_bib0012","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1046\/j.1523-1755.63.6s.2.x","article-title":"Incidence of latent mesangial IgA deposition in renal allograft donors in japan","volume":"63","author":"Suzuki","year":"2003","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.semnephrol.2025.151570_bib0013","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.semnephrol.2004.01.008","article-title":"Recurrent IgA nephropathy after renal transplantation","volume":"24","author":"Floege","year":"2004","journal-title":"Semin Nephrol"},{"issue":"5","key":"10.1016\/j.semnephrol.2025.151570_bib0014","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0272-6386(88)80027-1","article-title":"Recurrence of IgA nephropathy in renal allografts","volume":"12","author":"Berger","year":"1988","journal-title":"Am J Kidney Dis."},{"issue":"2","key":"10.1016\/j.semnephrol.2025.151570_bib0015","first-page":"241","article-title":"Disappearance of glomerular mesangial IgA deposits after renal allograft transplantation","volume":"33","author":"Silva","year":"1982","journal-title":"Transplantation."},{"issue":"11","key":"10.1016\/j.semnephrol.2025.151570_bib0016","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1016\/j.ekir.2020.08.018","article-title":"Prevalence, characteristics, and outcomes of incidental IgA glomerular deposits in donor kidneys","volume":"5","author":"Gaber","year":"2020","journal-title":"Kidney Int Rep."},{"issue":"6","key":"10.1016\/j.semnephrol.2025.151570_bib0017","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1172\/JCI109998","article-title":"Selective deposition of immunoglobulin a1 in immunoglobulin a nephropathy, anaphylactoid purpura nephritis, and systemic lupus erythematosus","volume":"66","author":"Conley","year":"1980","journal-title":"J Clin Invest."},{"issue":"3","key":"10.1016\/j.semnephrol.2025.151570_bib0018","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1440-1797.2007.00797.x","article-title":"The pathogenic role of IgA1 O-linked glycosylation in the pathogenesis of IgA nephropathy","volume":"12","author":"Barratt","year":"2007","journal-title":"Nephrology (Carlton)"},{"issue":"3","key":"10.1016\/j.semnephrol.2025.151570_bib0019","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1046\/j.1523-1755.2001.0590031077.x","article-title":"Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy","volume":"59","author":"Hiki","year":"2001","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.semnephrol.2025.151570_bib0020","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1172\/JCI5535","article-title":"Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies","volume":"104","author":"Tomana","year":"1999","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.semnephrol.2025.151570_bib0021","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1523-1755.2005.67107.x","article-title":"IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells","volume":"67","author":"Novak","year":"2005","journal-title":"Kidney Int"},{"issue":"10","key":"10.1016\/j.semnephrol.2025.151570_bib0022","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1681\/ASN.2018111156","article-title":"Glomerular immunodeposits of patients with IgA nephropathy are enriched for IgG autoantibodies specific for galactose-deficient iga1","volume":"30","author":"Rizk","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.semnephrol.2025.151570_bib0023","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1681\/ASN.2011050464","article-title":"The pathophysiology of IgA nephropathy","volume":"22","author":"Suzuki","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.semnephrol.2025.151570_bib0024","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.semnephrol.2018.05.018","article-title":"Role of mesangial-podocytic-tubular cross-talk in IgA nephropathy","volume":"38","author":"Leung","year":"2018","journal-title":"Semin Nephrol."},{"issue":"2","key":"10.1016\/j.semnephrol.2025.151570_bib0025","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.kint.2023.04.029","article-title":"IgA nephropathy: the lectin pathway and implications for targeted therapy","volume":"104","author":"Barratt","year":"2023","journal-title":"Kidney Int"},{"issue":"12","key":"10.1016\/j.semnephrol.2025.151570_bib0026","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1093\/ndt\/gfad140","article-title":"The complement system in IgAN: mechanistic context for therapeutic opportunities","volume":"38","author":"Duval","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"10.1016\/j.semnephrol.2025.151570_bib0027","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/s41588-023-01422-x","article-title":"Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy","volume":"55","author":"Kiryluk","year":"2023","journal-title":"Nat Genet"},{"issue":"9","key":"10.1016\/j.semnephrol.2025.151570_bib0028","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.34067\/KID.0002382022","article-title":"The gut and kidney crosstalk in immunoglobulin A nephropathy","volume":"3","author":"Sanchez-Russo","year":"2022","journal-title":"Kidney 360"},{"issue":"6","key":"10.1016\/j.semnephrol.2025.151570_bib0029","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nri2322","article-title":"The regulation of IgA class switching","volume":"8","author":"Cerutti","year":"2008","journal-title":"Nat Rev Immunol."},{"issue":"2","key":"10.1016\/j.semnephrol.2025.151570_bib0030","first-page":"295","article-title":"Glomerular deposition of food antigens in IgA nephropathy","volume":"73","author":"Sato","year":"1988","journal-title":"Clin Exp Immunol."},{"key":"10.1016\/j.semnephrol.2025.151570_bib0031","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1085922","article-title":"IgA nephropathy: pleiotropic impact of Epstein-Barr virus infection on immunopathogenesis and racial incidence of the disease","volume":"14","author":"Mestecky","year":"2023","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.semnephrol.2025.151570_bib0032","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.141289","article-title":"Immunoglobulin A nephropathy is characterized by anticommensal humoral immune responses","volume":"7","author":"Currie","year":"2022","journal-title":"JCI Insight"},{"issue":"11","key":"10.1016\/j.semnephrol.2025.151570_bib0033","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1016\/j.ekir.2023.08.007","article-title":"Variability in diagnosis and treatment of recurrent IgA nephropathy in kidney transplants: results of surveys of renal pathologists and nephrologists","volume":"8","author":"Haas","year":"2023","journal-title":"Kidney Int Rep."},{"issue":"Suppl 2","key":"10.1016\/j.semnephrol.2025.151570_bib0034","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/nep.13281","article-title":"Post-transplant immunoglobulin a deposition and nephropathy in allografts","volume":"23","author":"Sofue","year":"2018","journal-title":"Nephrology (Carlton)"},{"issue":"Suppl 3","key":"10.1016\/j.semnephrol.2025.151570_bib0035","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/nep.12255","article-title":"Recurrent glomerular disease after kidney transplantation: an update of selected areas and the impact of protocol biopsy","volume":"19","author":"Morozumi","year":"2014","journal-title":"Nephrology (Carlton)"},{"issue":"5","key":"10.1016\/j.semnephrol.2025.151570_bib0036","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/ki.2009.243","article-title":"The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification","volume":"76","author":"Cattran","year":"2009","journal-title":"Kidney Int."},{"issue":"5","key":"10.1016\/j.semnephrol.2025.151570_bib0037","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/ki.2009.168","article-title":"The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility","volume":"76","author":"Roberts","year":"2009","journal-title":"Kidney Int. Sep"},{"issue":"10","key":"10.1016\/j.semnephrol.2025.151570_bib0038","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.2215\/CJN.01170211","article-title":"The use of the Oxford classification of IgA nephropathy to predict renal survival","volume":"6","author":"Alamartine","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.semnephrol.2025.151570_bib0039","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.transproceed.2017.10.002","article-title":"Utility of Oxford classification in post-transplant immunoglobulin a nephropathy","volume":"49","author":"Agrawal","year":"2017","journal-title":"Transplant Proc."},{"issue":"12","key":"10.1016\/j.semnephrol.2025.151570_bib0040","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1097\/TP.0b013e318291de65","article-title":"Usefulness of Oxford classification in assessing immunoglobulin A nephropathy after transplantation","volume":"95","author":"Lim","year":"2013","journal-title":"Transplantation"},{"issue":"11","key":"10.1016\/j.semnephrol.2025.151570_bib0041","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1093\/ndt\/gfad097","article-title":"A novel prognostic nomogram predicts premature failure of kidney allografts with IgA nephropathy recurrence","volume":"38","author":"Bednarova","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"10.1016\/j.semnephrol.2025.151570_bib0042","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1111\/ajt.15400","article-title":"Clinical importance of the updated Oxford classification in allograft IgA nephropathy","volume":"19","author":"Park","year":"2019","journal-title":"Am J Transplant"},{"issue":"9","key":"10.1016\/j.semnephrol.2025.151570_bib0043","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1097\/TP.0000000000004640","article-title":"Evaluation of the modified Oxford score in recurrent IgA nephropathy in North American kidney transplant recipients: the Banff Recurrent Glomerulonephritis Working Group report","volume":"107","author":"Alachkar","year":"2023","journal-title":"Transplantation"},{"issue":"12","key":"10.1016\/j.semnephrol.2025.151570_bib0044","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1681\/ASN.2012101017","article-title":"Prediction of outcomes in crescentic IgA nephropathy in a multicenter cohort study","volume":"24","author":"Lv","year":"2013","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.semnephrol.2025.151570_bib0045","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1053\/j.ajkd.2004.09.030","article-title":"IgA nephropathy with crescents in kidney transplant recipients","volume":"45","author":"Kowalewska","year":"2005","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1016\/j.semnephrol.2025.151570_bib0046","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/ndt\/9.3.309","article-title":"Recurrent mesangial IgA nephritis following renal transplantation","volume":"9","author":"Odum","year":"1994","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"10.1016\/j.semnephrol.2025.151570_bib0047","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.2215\/CJN.00910121","article-title":"Recurrence of IgA nephropathy after kidney transplantation in adults","volume":"16","author":"Uffing","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.semnephrol.2025.151570_bib0048","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1186\/s12882-018-1135-7","article-title":"Recurrent glomerulonephritis following renal transplantation and impact on graft survival","volume":"19","author":"Jiang","year":"2018","journal-title":"BMC Nephrol."},{"issue":"1","key":"10.1016\/j.semnephrol.2025.151570_bib0049","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12882-022-02802-x","article-title":"Recurrence of IgA nephropathy after kidney transplantation: experience from the Swiss transplant cohort study","volume":"23","author":"Jager","year":"2022","journal-title":"BMC Nephrol"},{"issue":"6","key":"10.1016\/j.semnephrol.2025.151570_bib0050","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1093\/ndt\/gfr664","article-title":"IgA nephropathy recurs early in the graft when assessed by protocol biopsy","volume":"27","author":"Ortiz","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"10.1016\/j.semnephrol.2025.151570_bib0051","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1097\/TP.0000000000000962","article-title":"Long-term kidney transplant outcomes in primary glomerulonephritis: analysis from the ERA-EDTA registry","volume":"100","author":"Pippias","year":"2016","journal-title":"Transplantation."},{"key":"10.1016\/j.semnephrol.2025.151570_bib0052","doi-asserted-by":"crossref","DOI":"10.3389\/fneph.2022.923813","article-title":"Incidence, risk factors, and effect on allograft survival of glomerulonephritis post-transplantation in a United Kingdom population: cohort study","volume":"2","author":"Aguiar","year":"2022","journal-title":"Front Nephrol"},{"key":"10.1016\/j.semnephrol.2025.151570_bib0053","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.3389\/fimmu.2019.01332","article-title":"Immunoglobulin A nephropathy: recurrence after renal transplantation","volume":"10","author":"Moroni","year":"2019","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.semnephrol.2025.151570_bib0054","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/tri.13075","article-title":"Recurrence of IgA nephropathy after kidney transplantation in steroid continuation versus early steroid-withdrawal regimens: a retrospective analysis of the UNOS\/OPTN database","volume":"31","author":"Leeaphorn","year":"2018","journal-title":"Transpl Int."},{"issue":"1","key":"10.1016\/j.semnephrol.2025.151570_bib0055","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000519834","article-title":"Clinical predictors and prognosis of recurrent IgA nephropathy in the kidney allograft","volume":"2","author":"Kavanagh","year":"2022","journal-title":"Glomerular Dis"},{"key":"10.1016\/j.semnephrol.2025.151570_bib0056","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1277017","article-title":"Risk factors and outcomes of IgA nephropathy recurrence after kidney transplantation: a systematic review and meta-analysis","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.semnephrol.2025.151570_bib0057","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.bbrc.2018.12.014","article-title":"Difference in IgA1 O-glycosylation between IgA deposition donors and IgA nephropathy recipients","volume":"508","author":"Nakazawa","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"issue":"8","key":"10.1016\/j.semnephrol.2025.151570_bib0058","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/ctr.12389","article-title":"The risk of recurrent IgA nephropathy in a steroid-free protocol and other modifying immunosuppression","volume":"28","author":"Von Visger","year":"2014","journal-title":"Clin Transplant."},{"issue":"8","key":"10.1016\/j.semnephrol.2025.151570_bib0059","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1111\/j.1600-6143.2011.03667.x","article-title":"Steroids and recurrent IgA nephropathy after kidney transplantation","volume":"11","author":"Clayton","year":"2011","journal-title":"Am J Transplant."},{"issue":"10","key":"10.1016\/j.semnephrol.2025.151570_bib0060","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1097\/TP.0b013e3181705ad4","article-title":"Antithymocyte globulin (ATG) induction therapy and disease recurrence in renal transplant recipients with primary IgA nephropathy","volume":"85","author":"Berthoux","year":"2008","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.semnephrol.2025.151570_bib0061","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1007\/s10157-009-0179-1","article-title":"Tonsillectomy and steroid pulse (TSP) therapy for patients with IgA nephropathy: a nationwide survey of TSP therapy in Japan and an analysis of the predictive factors for resistance to TSP therapy","volume":"13","author":"Miura","year":"2009","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"10.1016\/j.semnephrol.2025.151570_bib0062","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1053\/j.ajkd.2014.06.036","article-title":"Tonsillectomy for IgA nephropathy: a meta-analysis","volume":"65","author":"Liu","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.semnephrol.2025.151570_bib0063","doi-asserted-by":"crossref","first-page":"18455","DOI":"10.1038\/s41598-023-45514-4","article-title":"Associations of corticosteroid therapy and tonsillectomy with kidney survival in a multicenter prospective study for IgA nephropathy","volume":"13","author":"Kawamura","year":"2023","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.semnephrol.2025.151570_bib0064","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.trim.2013.11.001","article-title":"Evaluation of tonsillectomy before kidney transplantation in patients with IgA nephropathy","volume":"30","author":"Sato","year":"2014","journal-title":"Transpl Immunol"},{"issue":"1","key":"10.1016\/j.semnephrol.2025.151570_bib0065","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000441852","article-title":"Tonsillectomy in a European cohort of 1,147 patients with IgA nephropathy","volume":"132","author":"Feehally","year":"2016","journal-title":"Nephron"},{"issue":"2","key":"10.1016\/j.semnephrol.2025.151570_bib0066","doi-asserted-by":"crossref","first-page":"317","DOI":"10.23876\/j.krcp.20.183","article-title":"Clinical significance of serum galactose-deficient immunoglobulin A1 for detection of recurrent immunoglobulin A nephropathy in kidney transplant recipients","volume":"40","author":"Park","year":"2021","journal-title":"Kidney Res Clin Pract"},{"issue":"3","key":"10.1016\/j.semnephrol.2025.151570_bib0067","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.transproceed.2017.02.003","article-title":"A novel biomarker for post-transplant recurrent IgA nephropathy","volume":"49","author":"Temurhan","year":"2017","journal-title":"Transplant Proc."},{"issue":"11","key":"10.1016\/j.semnephrol.2025.151570_bib0068","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1111\/tri.14009","article-title":"Glomerular galactose-deficient IgA1 detected in donor-derived and recurrent IgA nephropathy","volume":"34","author":"Su","year":"2021","journal-title":"Transpl Int"},{"issue":"11","key":"10.1016\/j.semnephrol.2025.151570_bib0069","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/sj.ki.5002185","article-title":"Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels","volume":"71","author":"Moldoveanu","year":"2007","journal-title":"Kidney Int"},{"issue":"9","key":"10.1016\/j.semnephrol.2025.151570_bib0070","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1093\/ndt\/gfl240","article-title":"IgA-containing immune complexes in the urine of IgA nephropathy patients","volume":"21","author":"Matousovic","year":"2006","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.semnephrol.2025.151570_bib0071","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s10157-018-1582-2","article-title":"Biomarkers for IgA nephropathy on the basis of multi-hit pathogenesis","volume":"23","author":"Suzuki","year":"2019","journal-title":"Clin Exp Nephrol"},{"issue":"5","key":"10.1016\/j.semnephrol.2025.151570_bib0072","doi-asserted-by":"crossref","first-page":"e98081","DOI":"10.1371\/journal.pone.0098081","article-title":"A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases","volume":"9","author":"Yanagawa","year":"2014","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.semnephrol.2025.151570_bib0073","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/ki.2012.197","article-title":"The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression","volume":"82","author":"Zhao","year":"2012","journal-title":"Kidney Int."},{"issue":"9","key":"10.1016\/j.semnephrol.2025.151570_bib0074","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1681\/ASN.2012010053","article-title":"Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy","volume":"23","author":"Berthoux","year":"2012","journal-title":"J Am Soc Nephrol."},{"issue":"6","key":"10.1016\/j.semnephrol.2025.151570_bib0075","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/j.1399-0012.2007.00730.x","article-title":"Serological and genetic factors in early recurrence of IgA nephropathy after renal transplantation","volume":"21","author":"Coppo","year":"2007","journal-title":"Clin Transplant."},{"issue":"4","key":"10.1016\/j.semnephrol.2025.151570_bib0076","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/ki.2015.158","article-title":"Recurrent IgA nephropathy is predicted by altered glycosylated IgA, autoantibodies and soluble CD89 complexes","volume":"88","author":"Berthelot","year":"2015","journal-title":"Kidney Int."},{"key":"10.1016\/j.semnephrol.2025.151570_bib0077","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2023.101850","article-title":"Serum galactose-deficient immunoglobulin A1 in recurrent immunoglobulin A nephropathy after kidney transplantation: a meta-analysis","volume":"79","author":"Gong","year":"2023","journal-title":"Transpl Immunol."},{"issue":"4","key":"10.1016\/j.semnephrol.2025.151570_bib0078","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196101","article-title":"Early post-transplant serum IgA level is associated with IgA nephropathy recurrence after kidney transplantation","volume":"13","author":"Garnier","year":"2018","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.semnephrol.2025.151570_bib0079","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 Guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"issue":"12","key":"10.1016\/j.semnephrol.2025.151570_bib0080","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1093\/ndt\/gfl506","article-title":"Does angiotensin blockade influence graft outcome in renal transplant recipients with IgA nephropathy?","volume":"21","author":"Courtney","year":"2006","journal-title":"Nephrol Dial Transplant."},{"issue":"5","key":"10.1016\/j.semnephrol.2025.151570_bib0081","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/ndt\/15.5.689","article-title":"A clinicopathological study of IgA nephropathy in renal transplant recipients: beneficial effect of angiotensin-converting enzyme inhibitor","volume":"15","author":"Oka","year":"2000","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.semnephrol.2025.151570_bib0082","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s40620-016-0314-5","article-title":"Treatment protocol with pulse and oral steroids for IgA nephropathy after kidney transplantation","volume":"29","author":"Messina","year":"2016","journal-title":"J Nephrol"},{"issue":"Suppl 2","key":"10.1016\/j.semnephrol.2025.151570_bib0083","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/nep.13272","article-title":"Effect of steroid pulse therapy on post-transplant immunoglobulin A nephropathy","volume":"23","author":"Matsukuma","year":"2018","journal-title":"Nephrology (Carlton)"},{"issue":"3","key":"10.1016\/j.semnephrol.2025.151570_bib0084","first-page":"103","article-title":"The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin: a two-year prospective trial","volume":"34","author":"Walker","year":"1990","journal-title":"Clin Nephrol."},{"issue":"1","key":"10.1016\/j.semnephrol.2025.151570_bib0085","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1681\/ASN.V131142","article-title":"Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy","volume":"13","author":"Ballardie","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2025.151570_bib0086","doi-asserted-by":"crossref","first-page":"166","DOI":"10.12659\/AOT.907167","article-title":"Clinical features, treatment and prognostic factors of post-transplant immunoglobulin A nephropathy","volume":"23","author":"Cordeiro Cabral","year":"2018","journal-title":"Ann Transplant."},{"issue":"2","key":"10.1016\/j.semnephrol.2025.151570_bib0087","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s13730-018-0341-2","article-title":"Recurrence of crescentic IgA nephropathy after renal transplantation","volume":"7","author":"Zagkotsis","year":"2018","journal-title":"CEN Case Rep."},{"issue":"4","key":"10.1016\/j.semnephrol.2025.151570_bib0088","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1159\/000186488","article-title":"IgA nephropathy with rapidly progressive course after kidney transplantation","volume":"58","author":"Robles","year":"1991","journal-title":"Nephron"},{"issue":"4","key":"10.1016\/j.semnephrol.2025.151570_bib0089","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1159\/000185892","article-title":"Loss of renal graft due to recurrent IgA nephropathy with rapidly progressive course: an unusual clinical evolution","volume":"54","author":"Diaz-Tejeiro","year":"1990","journal-title":"Nephron"},{"issue":"12","key":"10.1016\/j.semnephrol.2025.151570_bib0090","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/nep.12151","article-title":"Tonsillectomy ameliorates histological damage of recurrent immunoglobulin A nephropathy after kidney transplantation","volume":"18","author":"Hotta","year":"2013","journal-title":"Nephrology (Carlton)."},{"issue":"Suppl 20","key":"10.1016\/j.semnephrol.2025.151570_bib0091","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1399-0012.2009.01003.x","article-title":"Efficacy of tonsillectomy for patients with recurrence of IgA nephropathy after kidney transplantation","volume":"23","author":"Ushigome","year":"2009","journal-title":"Clin Transplant."},{"issue":"7","key":"10.1016\/j.semnephrol.2025.151570_bib0092","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1097\/TP.0b013e3181b75374","article-title":"Proteinuria-reducing effects of tonsillectomy alone in IgA nephropathy recurring after kidney transplantation","volume":"88","author":"Kennoki","year":"2009","journal-title":"Transplantation"},{"issue":"30","key":"10.1016\/j.semnephrol.2025.151570_bib0093","first-page":"2378","article-title":"[therapeutic effect of tonsillectomy on IgA nephropathy after kidney transplantation]","volume":"100","author":"Deng","year":"2020","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"1","key":"10.1016\/j.semnephrol.2025.151570_bib0094","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1681\/ASN.0000000000000242","article-title":"Treatment of IgA nephropathy: a rapidly evolving field","volume":"35","author":"El Karoui","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.semnephrol.2025.151570_bib0095","doi-asserted-by":"crossref","first-page":"239","DOI":"10.5500\/wjt.v13.i5.239","article-title":"Sodium-glucose cotransporter-2 inhibitor use in kidney transplant recipients","volume":"13","author":"Ramakrishnan","year":"2023","journal-title":"World J Transplant"},{"issue":"1","key":"10.1016\/j.semnephrol.2025.151570_bib0096","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.semnephrol.2025.151570_bib0097","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s11255-023-03711-0","article-title":"The first experience with the use of dapagliflozin in combination with ACEi for treatment of IgA nephropathy after kidney transplantation","volume":"56","author":"Basic-Jukic","year":"2024","journal-title":"Int Urol Nephrol"},{"issue":"5","key":"10.1016\/j.semnephrol.2025.151570_bib0098","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/ki.2014.143","article-title":"Endothelin and endothelin antagonists in chronic kidney disease","volume":"86","author":"Kohan","year":"2014","journal-title":"Kidney Int."},{"issue":"10417","key":"10.1016\/j.semnephrol.2025.151570_bib0099","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2025.151570_bib0100","series-title":"Presented at European Renal Association (ERA) Congress","article-title":"ALIGN Phase 3 primary endpoint analysis: Atrasentan shows significant reduction in protenuira in patients with IgA nephropathy","author":"Heerspink","year":"2024"},{"issue":"10084","key":"10.1016\/j.semnephrol.2025.151570_bib0101","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","article-title":"Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial","volume":"389","author":"Fellstrom","year":"2017","journal-title":"Lancet"},{"issue":"10405","key":"10.1016\/j.semnephrol.2025.151570_bib0102","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2025.151570_bib0103","doi-asserted-by":"crossref","first-page":"10693","DOI":"10.3389\/ti.2022.10693","article-title":"Enteric budesonide in transplant and native IgA nephropathy: real-world clinical practice","volume":"35","author":"Lopez-Martinez","year":"2022","journal-title":"Transpl Int"},{"issue":"5","key":"10.1016\/j.semnephrol.2025.151570_bib0104","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.kint.2023.02.012","article-title":"Targeted-release budesonide in recurrent IgA nephropathy after kidney transplantation","volume":"103","author":"Gandolfini","year":"2023","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.semnephrol.2025.151570_bib0105","doi-asserted-by":"crossref","first-page":"521","DOI":"10.4103\/1319-2442.284029","article-title":"Successful treatment of a patient with posttransplant IgA nephropathy with targeted release formulation of budesonide","volume":"31","author":"Lingaraj","year":"2020","journal-title":"Saudi J Kidney Dis Transpl"},{"issue":"17","key":"10.1016\/j.semnephrol.2025.151570_bib0106","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10173939","article-title":"Comparative long-term renal allograft outcomes of recurrent immunoglobulin A with severe activity in kidney transplant recipients with and without rituximab: an observational cohort study","volume":"10","author":"Chancharoenthana","year":"2021","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.semnephrol.2025.151570_bib0107","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1681\/ASN.2016060640","article-title":"A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction","volume":"28","author":"Lafayette","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.semnephrol.2025.151570_bib0108","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1681\/ASN.2017040367","article-title":"Targeting B cells and plasma cells in glomerular diseases: translational perspectives","volume":"29","author":"Schrezenmeier","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"15","key":"10.1016\/j.semnephrol.2025.151570_bib0109","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.2174\/138161211796197124","article-title":"The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib","volume":"17","author":"Cvek","year":"2011","journal-title":"Curr Pharm Des"},{"issue":"4","key":"10.1016\/j.semnephrol.2025.151570_bib0110","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.ekir.2018.03.001","article-title":"Bortezomib for reduction of proteinuria in IgA nephropathy","volume":"3","author":"Hartono","year":"2018","journal-title":"Kidney Int Rep"},{"issue":"3","key":"10.1016\/j.semnephrol.2025.151570_bib0111","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrd1982","article-title":"An APRIL to remember: novel TNF ligands as therapeutic targets","volume":"5","author":"Dillon","year":"2006","journal-title":"Nat Rev Drug Discov."},{"issue":"21","key":"10.1016\/j.semnephrol.2025.151570_bib0112","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12216927","article-title":"A proliferation-inducing ligand (APRIL) in the pathogenesis of immunoglobulin A nephropathy: a review of the evidence","volume":"12","author":"Mathur","year":"2023","journal-title":"J Clin Med."},{"key":"10.1016\/j.semnephrol.2025.151570_bib0113","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev.immunol.21.120601.141152","article-title":"BAFF and APRIL: a tutorial on B cell survival","volume":"21","author":"Mackay","year":"2003","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.semnephrol.2025.151570_bib0114","article-title":"The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies","volume":"3","author":"Cheung","year":"2023","journal-title":"Front Nephrol"},{"issue":"11","key":"10.1016\/j.semnephrol.2025.151570_bib0115","first-page":"1216","article-title":"Atacicept, a homodimeric fusion protein for the potential treatment of diseases triggered by plasma cells","volume":"9","author":"Gatto","year":"2008","journal-title":"Curr Opin Investig Drugs."},{"issue":"8","key":"10.1016\/j.semnephrol.2025.151570_bib0116","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.ekir.2022.05.017","article-title":"Randomized phase II JANUS study of atacicept in patients with IgA nephropathy and persistent proteinuria","volume":"7","author":"Barratt","year":"2022","journal-title":"Kidney Int Rep."},{"issue":"3","key":"10.1016\/j.semnephrol.2025.151570_bib0117","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","article-title":"Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria","volume":"8","author":"Lv","year":"2023","journal-title":"Kidney Int Rep."},{"issue":"7","key":"10.1016\/j.semnephrol.2025.151570_bib0118","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1681\/ASN.2014101000","article-title":"Current understanding of the role of complement in IgA nephropathy","volume":"26","author":"Maillard","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.semnephrol.2025.151570_bib0119","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/ckj\/sfv076","article-title":"Use of eculizumab in crescentic IgA nephropathy: proof of principle and conundrum?","volume":"8","author":"Ring","year":"2015","journal-title":"Clin Kidney J."},{"issue":"10","key":"10.1016\/j.semnephrol.2025.151570_bib0120","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.ajt.2023.05.031","article-title":"Eculizumab as a therapeutic approach for severe crescentic recurrence of immunoglobulin A nephropathy after kidney transplantation","volume":"23","author":"Duval","year":"2023","journal-title":"Am J Transplant"},{"issue":"7","key":"10.1016\/j.semnephrol.2025.151570_bib0121","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.transproceed.2017.02.044","article-title":"First treatment of relapsing rapidly progressive IgA nephropathy with eculizumab after living kidney donation: a case report","volume":"49","author":"Herzog","year":"2017","journal-title":"Transplant Proc."},{"issue":"1","key":"10.1016\/j.semnephrol.2025.151570_bib0122","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.kint.2023.09.027","article-title":"Results of a randomized double-blind placebo-controlled phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy","volume":"105","author":"Zhang","year":"2024","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.semnephrol.2025.151570_bib0123","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/ckj\/sfab294","article-title":"C5a receptor inhibitor avacopan in immunoglobulin A nephropathy: an open-label pilot study","volume":"15","author":"Bruchfeld","year":"2022","journal-title":"Clin Kidney J"},{"issue":"11","key":"10.1016\/j.semnephrol.2025.151570_bib0124","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/j.ekir.2020.08.003","article-title":"Safety, tolerability and efficacy of narsoplimab, a novel MASP-2 inhibitor for the treatment of IgA nephropathy","volume":"5","author":"Lafayette","year":"2020","journal-title":"Kidney Int Rep."},{"issue":"4","key":"10.1016\/j.semnephrol.2025.151570_bib0125","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2215\/CJN.0000000000000384","article-title":"Phase 2 trial of cemdisiran in adult patients with IgA nephropathy: a randomized controlled trial","volume":"19","author":"Barratt","year":"2024","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929525000075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929525000075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T18:20:57Z","timestamp":1762280457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929525000075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":125,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0270929525000075"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2025.151570","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-transplant IgA Nephropathy","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2025.151570","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"151570"}}